logo

For the Inventor, By the Inventor

Montreal, Canada

Alethia Biotherapeutics Inc.

USPTO Granted Patents = 19

% Expired Patents = 15.8



Forward Citations = 105

Loading Chart...
Loading Chart...

7 inventors (with patents filed for the assignee):

goldMedal Gilles Bernard Tremblay (19 out of 29 patents)

silverMedal Mario Filion (19 out of 26 patents)

bronzeMedal Roy Rabindranauth Sooknanan (9 out of 16 patents)

4.  Traian Sulea (5 out of 34 patents)

5.  Matthew Stuible (4 out of 5 patents)

6.  Anna N Moraitis (3 out of 6 patents)

7.  Elisabeth Viau (1 out of 1 patent)


19 patents:

1. 9822170 - Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer (2017-11-21),
2. 9512211 - Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume (2016-12-06),
3. 9493562 - Anti-Siglec-15 antibodies (2016-11-15),
4. 9393302 - Antibodies against kidney associated antigen 1 and antigen binding fragments thereof (2016-07-19),
5. 9388242 - Nucleic acids encoding anti-Siglec-15 antibodies (2016-07-12),
6. 9067984 - Methods of impairing osteoclast differentiation using antibodies that bind Siglec-15 (2015-06-30),
7. 9040246 - Methods of making antibodies that bind polypeptides involved in the process of bone remodeling (2015-05-26),
8. 8937163 - Antibodies against kidney associated antigen 1 and antigen binding fragments thereof (2015-01-20),
9. 8900579 - Siglec-15 antibodies in treating bone loss-related disease (2014-12-02),
10. 8802826 - Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume (2014-08-12),
11. 8741289 - Siglec 15 antibodies in treating bone loss-related disease (2014-06-03),
12. 8580257 - Antibodies that specifically block the biological activity of kidney associated antigen 1 (KAAG1) (2013-11-12),
13. 8540988 - Antibodies that bind polypeptides involved in the process of bone remodeling (2013-09-24),
14. 8444975 - Method for inhibiting bone resorption (2013-05-21),
15. 8431126 - Antibodies that bind polypeptides involved in the process of bone remodeling (2013-04-30),
Company Overview
Alethia Biotherapeutics Inc. is a biotechnology company based in Montreal, Canada, focused on developing innovative therapeutic solutions for various diseases. The company specializes in the research and development of biopharmaceuticals, leveraging advanced technologies to create targeted treatments. Alethia's expertise spans multiple domains, including immunotherapy and precision medicine, aiming to address unmet medical needs and improve patient outcomes through cutting-edge scientific advancements.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

19 Patents

#56 in Montreal

#778 in Canada

#32,693 in the World

Montreal, CA
Montreal, Canada

Alethia Biotherapeutics Inc.

Forward Citations = 105

7 inventors:

goldMedal Gilles Bernard Tremblay (19 out of 29 patents)

silverMedal Mario Filion (19 out of 26 patents)

bronzeMedal Roy Rabindranauth Sooknanan (9 out of 16 patents)

4.  Traian Sulea (5 out of 34 patents)

5.  Matthew Stuible (4 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Alethia Biotherapeutics Inc.. Retrieved from https://idiyas.com/company/alethia-biotherapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…